Addex Therapeutics Stock Today
| ADXN Stock | USD 8.71 0.09 1.04% |
Performance0 of 100
| Odds Of DistressOver 83
|
Addex Therapeutics is selling at 8.71 as of the 1st of December 2024; that is 1.04 percent increase since the beginning of the trading day. The stock's open price was 8.62. Addex Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Addex Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of December 2023 and ending today, the 1st of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of January 2020 | Category Healthcare | Classification Health Care |
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland. The company has 1.07 M outstanding shares of which 18.42 K shares are presently shorted by private and institutional investors with about 0.14 trading days to cover. More on Addex Therapeutics
Moving against Addex Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Addex Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Swiss Performance Extra, NASDAQ Health Care, Swiss Performance Index, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAddex Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Addex Therapeutics' financial leverage. It provides some insight into what part of Addex Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Addex Therapeutics (ADXN) is traded on NASDAQ Exchange in USA. It is located in Chemin des Mines, 9, Geneva, Switzerland, 1202 and employs 23 people. Addex Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.31 M. Addex Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.07 M outstanding shares of which 18.42 K shares are presently shorted by private and institutional investors with about 0.14 trading days to cover.
Addex Therapeutics currently holds about 8.81 M in cash with (7.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4.
Check Addex Therapeutics Probability Of Bankruptcy
Ownership AllocationAlmost 99.84 percent of Addex Therapeutics outstanding shares are held by general public with 0.16 % by other corporate entities.
Check Addex Ownership Details
Addex Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 3 K | |
| Adar1 Capital Management Llc | 2024-09-30 | 1000 |
Addex Therapeutics Historical Income Statement
Addex Stock Against Markets
Addex Therapeutics Corporate Management
| Timothy Dyer | CEO CoFounder | Profile | |
| Werner Henrichi | Consultant | Profile | |
| Mikhail Kalinichev | Head Science | Profile | |
| JeanPhilippe Rocher | Head Chemistry | Profile | |
| Roger MD | Chief Director | Profile | |
| Lnaic Teyssdou | Head Finance | Profile | |
| Robert Lutjens | Head Biology | Profile |
Already Invested in Addex Therapeutics?
The danger of trading Addex Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Addex Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Addex Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Addex Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (21.76) | Revenue Per Share 1.2 | Quarterly Revenue Growth (0.82) | Return On Assets (0.62) | Return On Equity (1.26) |
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.